# Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

> **NCT06377930** · PHASE2 · COMPLETED · sponsor: **Rapport Therapeutics Inc.** · enrollment: 30 (actual)

## Conditions studied

- Focal Onset Seizures

## Interventions

- **DRUG:** RAP-219

## Key facts

- **NCT ID:** NCT06377930
- **Lead sponsor:** Rapport Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-10
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06377930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06377930, "Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06377930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*